- Home
- MGEE vs CPRX Comparison
MGEE vs CPRX Comparison
Compare MGEE & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGEE
- CPRX
- Stock Information
- Founded
- MGEE 1855
- CPRX 2002
- Country
- MGEE United States
- CPRX United States
- Employees
- MGEE N/A
- CPRX N/A
- Industry
- MGEE Electric Utilities: Central
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- MGEE Energy
- CPRX Health Care
- Exchange
- MGEE Nasdaq
- CPRX Nasdaq
- Market Cap
- MGEE 3.1B
- CPRX 2.9B
- IPO Year
- MGEE N/A
- CPRX 2006
- Fundamental
- Price
- MGEE $82.66
- CPRX $23.60
- Analyst Decision
- MGEE Sell
- CPRX Strong Buy
- Analyst Count
- MGEE 2
- CPRX 5
- Target Price
- MGEE $79.00
- CPRX $32.60
- AVG Volume (30 Days)
- MGEE 116.4K
- CPRX 1.4M
- Earning Date
- MGEE 11-05-2025
- CPRX 11-05-2025
- Dividend Yield
- MGEE 2.31%
- CPRX N/A
- EPS Growth
- MGEE 12.85
- CPRX 44.94
- EPS
- MGEE 3.69
- CPRX 1.71
- Revenue
- MGEE $708,516,000.00
- CPRX $578,196,000.00
- Revenue This Year
- MGEE $10.69
- CPRX $16.59
- Revenue Next Year
- MGEE $3.32
- CPRX $8.42
- P/E Ratio
- MGEE $22.24
- CPRX $13.81
- Revenue Growth
- MGEE 8.39
- CPRX 25.56
- 52 Week Low
- MGEE $80.67
- CPRX $19.05
- 52 Week High
- MGEE $106.76
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- MGEE 46.60
- CPRX 68.58
- Support Level
- MGEE $80.94
- CPRX $22.23
- Resistance Level
- MGEE $82.87
- CPRX $23.62
- Average True Range (ATR)
- MGEE 1.48
- CPRX 0.88
- MACD
- MGEE -0.11
- CPRX 0.09
- Stochastic Oscillator
- MGEE 47.92
- CPRX 88.96
About MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).